Abstract
Recent studies have found that cytoskeleton-associated protein 2 like (CKAP2L), an important oncogene, is involved in the biological behavior of many malignant tumors, but its function in the malignant course of glioma has not been confirmed. The main purpose of this study was to clarify the relationship between prognostic clinical characteristics of glioma patients and CKAP2L expression using data collected from the GEPIA, HPA, CGGA, TCGA, and GEO databases. CKAP2L expression was significantly increased in glioma. Further, Kaplan-Meier plots revealed that increased expression of CKAP2L was associated with shorter survival time of glioma patients in datasets retrieved from multiple databases. Cox regression analysis indicated that CKAP2L can serve as an independent risk factor but also has relatively reliable diagnostic value for the prognosis of glioma patients. The results of gene set enrichment analysis suggested that CKAP2L may play a regulatory role through the cell cycle, homologous recombination, and N-glycan biosynthesis cell signaling pathways. Several drugs with potential inhibitory effects on CKAP2L were identified in the CMap database that may have therapeutic effects on glioma. Finally, knockdown of CKAP2L inhibited the proliferation and invasion of cells by reducing the expression level of cell cycle-related proteins. This is the first study to demonstrate that high CKAP2L expression leads to poor prognosis in glioma patients, providing a novel target for diagnosis and treatment of glioma.
Highlights
Gliomas are primary malignant tumors derived from neural progenitor cells and glial cells that account for the vast majority of intracranial tumors [1, 2]
Gene Expression Omnibus (GEO) is a public repository of functional genomic data obtained via high-throughput and next-generation sequencing [17], which has been widely used for bioinformatics analysis of tumor characteristics
The results were consistent in thousands of tissue samples, reliably indicating that high expression levels of cytoskeleton-associated protein 2 like (CKAP2L) led to poor prognosis in glioma patients
Summary
Gliomas are primary malignant tumors derived from neural progenitor cells and glial cells that account for the vast majority of intracranial tumors [1, 2]. To improve the prognosis of patients with glioma, many scientists have made unremitting efforts to form the standardized therapeutic principles that have been developed to maximize tumor resection, reduce tumor load, and administer adjuvant radiotherapy and chemotherapy [4]. In an effort to identify more reliable biomarkers, researchers have established a variety of publicly available databases, including TCGA and CGGA, with sufficient sample sizes and comprehensive clinical information Mining this data provides guidance for molecular typing and drug target development for glioma, laying the foundation for development of a whole chain of precision medicine for glioma [6, 7]. Many effective biomarkers have been identified through database analysis methods for the diagnosis and targeted treatment of glioma, including CD276, BioMed Research International
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
